Alopecia areata

This study tests two daily doses (50 mg and 100 mg) of the medicine ritlecitinib in about 550 people aged 12 and older with severe alopecia areata, a condition causing significant hair loss on the scalp and body. The 50 mg dose is already approved, and researchers want to see if …

This trial tests whether upadacitinib, an oral medication that calms the immune system, can help children with severe alopecia areata—a condition where the immune system attacks hair follicles, causing significant hair loss. Children aged 6 to 17 with at least 50% scalp hair loss…

This early-stage study tests a new drug called HCW9302 in 30 adults with alopecia areata, a condition causing patchy or total hair loss. The drug is an IL-2 fusion protein given by injection. The main goal is to check safety and find the right dose for future studies, not to prov…

This phase 3 trial tests whether the experimental drug ritlecitinib can safely and effectively regrow hair in people aged 12 and older with moderate alopecia areata, a condition causing patchy hair loss. Participants take a daily capsule for 24 weeks, with some receiving placebo.…

This study tests whether baricitinib, a daily pill, can safely regrow hair in children aged 6 to 17 with severe alopecia areata (patchy hair loss). About 595 kids will receive either the drug or a placebo for 36 weeks, then all can get the drug for up to 2 years. The goal is to s…

This study tests a new drug called LY4005130 for adults with severe alopecia areata, a condition causing significant hair loss. About 60 participants will receive either the drug or a placebo intravenously. The goal is to see if the drug can regrow hair and to check for side effe…

This study tests if dupilumab can help children aged 6 to 17 with moderate to severe alopecia areata regrow hair. About 76 participants will receive either the drug or a placebo for 48 weeks, followed by an open-label extension. The main goal is to measure changes in scalp hair l…

This trial is testing an experimental oral medication, VC005, in adults with severe alopecia areata—an autoimmune condition that causes patchy or complete hair loss. Participants will take either VC005 or a placebo daily for 24 weeks. The main goal is to see if the drug can reduc…

This program offers early access to upadacitinib (Rinvoq) for people with Crohn's disease, ulcerative colitis, certain types of arthritis, or atopic dermatitis who have no other suitable treatments and cannot join ongoing clinical trials. A doctor must decide if the potential ben…

This study tests a drug called deuruxolitinib in Japanese adults aged 18-65 with severe alopecia areata, an autoimmune condition causing significant scalp hair loss. Participants must have at least 50% hair loss. The trial measures how well the drug regrows hair and how satisfied…

This study tests a new drug called BG-A3004 for the first time in humans. It aims to check the drug's safety and how the body processes it in healthy volunteers and people with immune-related skin diseases. The study is split into two parts: single dose in healthy people and mult…

This phase 3 trial tests whether upadacitinib (Rinvoq) can help regrow hair in people with severe alopecia areata, an autoimmune condition that causes patchy or total hair loss. About 1500 adults and teens will receive either the drug or a placebo daily for up to 160 weeks. The m…

This study tests whether transplanting healthy gut bacteria can help people with alopecia areata, an autoimmune disease that causes patchy or total hair loss. Forty adults with moderate to severe hair loss will take either antibiotic and microbiota transplant capsules or a placeb…

This phase 2 trial tests whether ruxolitinib, a drug already approved for certain blood disorders, can help regrow hair in people with APECED, a rare immune condition that often causes severe alopecia areata. About 70 participants aged 12 to 75 will take the pill twice daily for …

This study tests whether dupilumab, a drug used for allergies and eczema, can help regrow hair in people with moderate-to-severe alopecia areata who also have allergies or high IgE levels. Participants receive weekly injections of dupilumab or a placebo for 48 weeks, followed by …

This study tests a drug called LAD603 in 136 adults with severe to very severe alopecia areata, a condition causing significant hair loss. Participants will receive either the drug or a placebo to see if it helps regrow hair and is safe. The main goal is to measure changes in hai…

This study is monitoring the safety and effectiveness of Litfulo (Ritlecitinib) in 3,000 people with severe alopecia areata, a condition causing patchy hair loss. Participants take the drug as prescribed in real-world clinics across Korea. Researchers will track side effects and …

This study looks at the long-term safety and effects of the drug ritlecitinib for severe alopecia areata, a condition causing significant hair loss. It involves 140 teens who previously completed Pfizer studies on this drug. Participants take a daily capsule for up to 3 years, wi…

This early-stage trial tests a new drug called IBI3013, which blocks a protein (IL-15) involved in immune attacks. It includes 160 people: healthy volunteers first, then people with active vitiligo or severe alopecia areata. The main goal is to check safety and how the drug moves…

This study tests an experimental oral drug called NXC736 in 73 adults with moderate to severe alopecia areata, a condition causing patchy or total hair loss. Participants are randomly assigned to receive either NXC736 or a placebo for 12 weeks. The main goal is to see if the drug…

This study tests a daily pill called abrocitinib for people with Down syndrome who have eczema or a type of hair loss. About 56 participants will take the drug for up to 60 weeks to see if it safely controls their skin or scalp condition. The goal is to manage symptoms, not cure …

This study compares two common drugs, cyclosporine and methotrexate, to treat moderate-to-severe alopecia areata in children aged 2-17. The goal is to see which medicine helps regrow hair better over 9 months. Participants and their parents choose which treatment to try, and doct…

This study tests an oral drug called deuruxolitinib in teenagers aged 12 to 17 who have lost at least half their scalp hair due to alopecia areata. The goal is to see if the drug can safely regrow hair. Participants will be randomly assigned to receive either the drug or a placeb…

This study tests whether microneedling combined with one of three substances—lactic acid, vitamin D3, or a steroid (triamcinolone acetonide)—can help regrow hair in people with patchy alopecia areata. Eighty-eight participants will receive one of the four treatments (including a …

This early-stage trial tests a drug called FB102 in 32 adults with severe to very severe alopecia areata, a condition causing significant hair loss. Half receive the drug and half a placebo, all by IV. The main goal is to check safety, but researchers will also measure hair regro…

This program provides early access to ritlecitinib for people with severe alopecia areata who have lost at least half of their scalp hair and have not responded to or cannot tolerate standard treatments. The goal is to offer a potential treatment option before the drug is fully a…

This early-stage study tests whether ALD-102, a solution injected into the scalp, is safe and can help regrow hair in people with alopecia areata. About 24 adults aged 18-55 will receive either the drug, a placebo (saline), or no treatment in different scalp areas. The main goal …

This study is testing a new laser called PALLAS to treat skin diseases like vitiligo, psoriasis, alopecia areata, and atopic dermatitis. About 50 people will receive UVB laser treatments twice a week for up to 3 months. The goal is to see if the laser improves the skin condition …

This study asks whether a red glow seen under ultraviolet light on the scalp can predict how well hair regrows in people with a type of hair loss called limited plaque alopecia areata. Adults who are already scheduled to receive corticosteroid injections as part of their regular …

This study follows 1,000 people with chronic inflammatory skin diseases, such as eczema, psoriasis, and rosacea, over time. Researchers will collect detailed clinical data and biological samples to see which factors correlate with disease activity and progression. The goal is to …

This registry will follow 1500 adolescents aged 12-17 with severe alopecia areata, a condition causing hair loss. Researchers will collect data from routine dermatology visits to better understand the disease's natural history, how it is managed, and what treatments are used. The…

This study investigates whether two substances in the blood—GPX4 and MDA—are linked to the severity of alopecia areata, a condition that causes patchy hair loss. Researchers will compare levels of these markers in 104 people with alopecia areata and 52 healthy volunteers. The goa…

This study aims to understand how alopecia areata, vitiligo, and hidradenitis suppurativa affect the quality of life and daily functioning of teenagers and adults. Researchers will collect information from nearly 2,800 participants across multiple countries using surveys and skin…

This observational study will follow about 5,000 adults with alopecia areata across North America to learn more about the condition, how it changes over time, and how it is currently treated. Researchers will collect data from doctor visits and patient surveys to better understan…